Saturday, July 11, 2026

Drug profile · INN

xenon xe-129 hyperpolarized

xenon xe-129 hyperpolarized (XENOVIEW) is a mri contrast agent. Route of administration: inhalation. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — xenon xe-129 hyperpolarized
US status
approved
Class
Route
INHALATION
Patents
0
Programs
4
Data quality
0.84

Quick answer

xenon xe-129 hyperpolarized (XENOVIEW) is a mri contrast agent. Route of administration: inhalation. Current US regulatory status: approved.

Key facts

INN xenon xe-129 hyperpolarized
Brand XENOVIEW
Mechanism MRI contrast agent
Route INHALATION
Formulation GAS

Mechanism of action

MRI contrast agent

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Hyperpolarized 129Xenon gas Phase 2 · United Therapeutics Europe · Pulmonary Vascular Disease
  2. Hyperpolarized 13C-Pyruvate injection Phase 2 · Hospital Authority · Gynecologic Cancer
  3. Hyperpolarized Xe129 Phase 2 · Regeneron UK · Pulmonary Artery Hypertension
  4. Hyperpolarized xenon Phase 1 · United Therapeutics Europe · Lung Disease

Frequently asked questions

What is xenon xe-129 hyperpolarized?

xenon xe-129 hyperpolarized (XENOVIEW) is a mri contrast agent. Route of administration: inhalation. Current US regulatory status: approved.

What is the brand name for xenon xe-129 hyperpolarized?

XENOVIEW is a marketed brand name for xenon xe-129 hyperpolarized. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of xenon xe-129 hyperpolarized?

xenon xe-129 hyperpolarized has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.